Seroprevalence of severe acute respiratory syndrome (SARS) coronavirus antibody among health care workers (Ip et al., pp. e116--8). The study examines the risk of infection for clinical health care workers who care for patients with SARS. The seroprevalence of SARS-associated coronavirus antibody was higher among health care workers who worked in SARS hospital wards than among those who worked in non-SARS wards. The highest rates of infection of health care workers on these wards were found among nurses (11.6%) and health care assistants (11.8%).

An alternative vaccine against smallpox (McCurdy et al., pp. 1749--53). This article suggests that modified vaccinia Ankara (MVA) is a potential alternative to the current smallpox vaccine. The MVA virus has less virulence and a better immune response than the current vaccine.

Efficacy of HAART for HIV type 2 (HIV-2) infection (Mullins et al., pp. 1771--9). In a series of 10 patients with HIV-2 infection, the CD4^+^ cell count and viral load were found to correlate with clinical status. However, the data suggest that drug regimens effective against HIV-1 infection may not demonstrate similar efficacy against HIV-2 infection.

Glutamine improves drug malabsorption in patients with AIDS (Bushen et al., pp. 1764--70). This study examined the effects of glutamine and alanyl-glutamine on diarrhea and antiretroviral drug levels in patients with AIDS in northeast Brazil. Clinical symptom scores improved significantly with high-dose alanyl-glutamine or glutamine. Antiretroviral drug levels improved by 113% in subjects given high-dose alanyl-glutamine (*P* = .02), by 8% in those given low-dose alanyl-glutamine, and by 14% in those given glutamine, compared with control subjects given glycine, in whom drug levels fell by 32% (see figure). Glutamine analogues may improve intestinal symptoms and drug absorption in patients with AIDS and diarrhea in tropical countries.

Methicillin-resistant ***Staphylococcus aureus*** (MRSA) response to vancomycin (Moise-Broder et al., pp. 1700--5). The accessory gene regulator *(agr)* of *S. aureus* controls many of the organism\'s virulence pathways. It upregulates many secreted virulence factors and downregulates cell-bound factors. Previous studies have suggested that polymorphisms at the *agr* locus may be related to glycopeptide susceptibility. In this study of MRSA isolates, the *agr* group II polymorphism was found to be an independent predictor of vancomycin treatment failure. This is the first report linking a specific genetic polymorphism to antimicrobial treatment failure.
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